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CLINICAL EVALUATION OF A SPECIFIC BENZODIAZEPINE
ANTAGONIST (RO 15-1788)
Studies in Elderly Patients after Regional Anaesthesia under Benzodiazepine Sedation
B. RICOU, A. FORSTER, A. BRUCKNER, P. CHASTONAY AND
M. GEMPERLE
Several drugs have been administered to patients
in an attempt to antagonize the clinical effects of
the benzodiazepines (BZD). Of these, physostig-
mine seemed to be the most effective (Caldwell and
Gross, 1982), although it was not totally reliable
(Garber et al., 1980). The efficacy of naloxone
(Jordan et al., 1980; Forster, Morel et al., 1983)
and aminophylline (Stirt, 1981; Meyer, Weis and
Muller, 1984) remains controversial.
Recently, a new class of BZD, the imidazodiaz-
epines, have been developed, some of which
specifically antagonize the action of the BZD by
competition at BZD-receptors in the central
nervous system (Hunkeler et al., 1981). Of these,
RO 15-1788 (RO) has been selected for clinical
trials because of its lack of toxicity and its efficacy
in antagonizing the effects of BZD in man
(Darragh et al., 1981). The anticonvulsant action
of RO (Scollo-Lavizzari, 1984) and the electro-
physiological modifications described by Schopf
and colleagues (1984) are the only objective
evidence of agonist effect in man. However,
subjective symptoms such as drowsiness and
dizziness have been described in volunteers when
RO was administered alone (Darragh et al., 1983)
and other objective agonist properties have been
demonstrated in animals (Dantzer and Perio,
1982). Depending on the details of the investiga-
tion and dose given, inverse agonist effects of RO,
such as anxiety, have been described in man (Louis
et al., 1984) and animals (File, Lister and Nutt,
1982).
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SUMMARY
The efficacy, usefulness and side effects of RO
15-1788 (RO), a specific benzodiazepine (BZD)
antagonist, have been evaluated. Sixty-two
patients (ASA l-lll, mean age 72±9yr)
scheduled for urological surgery under regional
anaesthesia and BZD sedation received placebo
or RO in a randomized, double-blind fashion at
the end of the procedure, folio wing sedation with
midazolam. When compared with placebo, RO
improved alertness and collaboration for 15 min,
and suppressed anterograde amnesia for 60 min.
No major side effect was noted, although five
patients became anxious after administration of
RO. Two cases of a paradoxical reaction to
midazolam were treated successfully by RO.
Transurethral resection of tumours of the
bladder or prostate is usually performed under
regional anaesthesia, because it allows earlier
recognition of complications such as water
intoxication (Desmond, 1970) and permits better
monitoring of the patient's clinical state (Marx and
Orkin, 1962).
Nevertheless, adequate preoperative and per-
operative sedation is desirable since it permits the
use of regional anaesthesia in a relaxed and
co-operative patient (Greenblatt, Shader and
Abernethy, 1983). In addition, it improves
operative conditions and the acceptability of these
procedures for the patients, who must lie
immobile in an uncomfortable position (lithotomy)
on a hard operating table, for more than 1 h.
Sedation can be obtained easily with a non-
analgesic sedative agent such as a BZD, which
produces good anxiolysis and anterograde amnesia
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without inducing major cardiorespiratory depres-
sion, even in elderly patients (Pearce, 1974).
However, at the end of surgery it is desirable to
have an awake, well-orientated and collaborative
patient so that better understanding and partici-
pation in postoperative care can be obtained. Since
the intensity and the duration of the BZD sedation
are difficult to predict—particularly in elderly
patients (Kanto et al., 1979; Greenblatt, Sellers
and Shades, 1982; Greenblatt et al., 1984)—the
reversal of the sedation with a specific BZD
antagonist could be useful.
The purpose of the present study was to
confirm the efficacy of RO in a clinical situation,
to assess its duration of action and its side effects,
and to determine whether its routine administra-
tion in elderly patients after regional anaesthesia
under BZD sedation was of any value.
PATIENTS AND METHODS
After approval by the Hospital Ethical Committee,
62 patients of both sexes, ASA classes I—III,
scheduled for transurethral resection of tumours
of the prostate or bladder, gave their informed
consent and participated in the study.
All patients with hypersensitivity to BZD,
impairment of consciousness, behaviour or
memory, hepatic or renal insufficiency (diagnosed
on biochemical tests), or who were receiving
prolonged treatment with sedative or psychotropic
drugs were excluded from the study.
Preoperative sedation and anaesthetic technique
On the evening before operation, all patients
received chloral hydrate 20 ml by mouth. On the
day of the operation, 1 h before the arrival of the
patient in the operating room, midazolam 7.5 mg
was administered by mouth to patients of less than
60 kg, and midazolam 15 mg to those weighing
more than 60 kg.
On arrival of the patient in the operating room,
a cannula (Venflon 17-gauge) was inserted to a
peripheral vein, and an infusion of lactated
Ringer's solution was started. Spinal anaesthesia
was performed with amethocaine in 58 patients,
and in one patient in each group extradural
anaesthesia was instituted with lignocaine or
bupivacaine (segmental level of T8-10.).
Once the quality of the regional anaesthesia had
been assessed, midazolam 0.05 mg kg"1 followed
by incremental doses of 1.5 mg was injected i.v. to
obtain the desired state of sedation (patient asleep,
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but reusable on command). When the degree of
sedation became insufficient, a further dose of
midazolam 1.5 mg was injected to maintain the
desired state of sedation (unless it appeared likely
that the operation would be completed within the
next 15 min).
At the end of surgery, either RO 0.1 mg kg"1 or
placebo (solvent = glycholic acid, 40% NaOH,
lecithin, HC1, H,O) was injected over 30 s, in a
double-blind and randomized fashion.
Measured variables
Routine laboratory tests were performed before
and after the operation to exclude an impaired
state of consciousness resulting from water
intoxication. Routine haemodynamic variables
were measured throughout the study.
In order to assess the effects of RO on the
central nervous system, the degrees of sedation, of
comprehension and collaboration and temporo-
spatial orientation were evaluated the day before
surgery, on arrival in the operating area, 15 min
after the injection of midazolam, and at 5, 15, 30,
60, 120 and 240 min after the administration of
RO or placebo. No determination was made just
before the end of surgery, in order to avoid any
stimulation of the patients, which could have
modified their response to the injection of the test
drug (placebo or RO). The evaluation of the
central nervous system was scored as indicated in
table I. Sedation was evaluated as described
elsewhere (Nisbet and Norris, 1963) and degrees
of comprehension and collaboration were deter-
mined by asking the patients to execute simple
gestures such as inflating the cheeks or raising
their hands.
TABLB I. Scoring of testtfor CNS evaluation
Sedation
0 = awake and tense.
1 •=• awake and relaxed
2 = drowsy
3 = asleep but arousable
4 => asleep, not arousable
Comprehension and collaboration
0 = order executed on command
1 = order executed on imitation
2 = order not excuted at all
Temporo-spatial orientation
0 = totally disorientated
1 = orientated in one of the two modes
2 = orientated in both modes
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Vital capacity, measured with a Wright spiro-
meter, was considered more as an objective test
of comprehension and collaboration, than as an
evaluation of respiratory volume. Presence and
duration of anterograde amnesia were evaluated
by standard methods (Benton, 1953) and by
asking patients to recall the different events of the
day of the operation such as arrival in the
operating room, the anaesthetic procedure and
the surgery.
The results are presented as mean values ± stan-
dard deviation (SD). Data from the same group
were statistically analysed by paired t test or
one-way analysis of variance; when the two
groups were compared, either unpaired t test or
Wilcoxon rank sum test was used depending on
the distribution. The Chi-square test was utilized
for non-parametric data. The differences were
considered statistically significantly if P < 0.05.
RESULTS
Thirty patients received the antagonist RO
15-1788 (group RO) and 30 the placebo (group
PL). Two other patients at first included in the
study had to be excluded because of an unexpected
reaction to midazolam.
Physical characteristics were similar in both
groups (table II). There were no differences in
medication or reasons for operation between the
groups.
The total dose of midazolam injected during
the operation was comparable in both
TABLE II. Physical characteristics of the patients (mean
values ±SD)
PL group
(n = 30)
RO group
Age(yr)
Sex (F/M)
Weight (kg)
Height (cm)
71.5±8.6
3/27
73.1±11.2
169±8
70.2 ±9.6
3/28
76.6±12.8
170±7
groups: 4.33 ± 1.86 mg in the PL group and
4.77 ± 2.44 mg in the RO group. The time interval
between the first injection of midazolam and
placebo or RO was similar being, respectively,
58.1 ±25.7 min and 59.46±26.7 min.
Apart from an increase in blood glucose
concentration and a decrease in serum sodium
concentration which were not clinically important,
no significant changes occurred in the other
laboratory variables. All the haemodynamic varia-
bles remained stable throughout the study, with
the exception of a significant decrease in arterial
pressure after midazolam, which was not relevant
clinically.
The effects of placebo or RO on midazolam-
induced sedation are summarized in figure 1 and
table III. The preoperative degree of alertness
and of sedation induced by administration of
midazolam by mouth or i.v. was similar in both
groups up to 15 min before the end of surgery.
However, following the injection of the placebo or
RO, the level of sedation was significantly less in
the RO group when compared with the placebo
3 -
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2 -
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1 -
O-l
DRO
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I
B«fore Md+ Mld+
op. 60 min 15 min
15 60 120
Time after PL or RO (min)
240
FIG. 1. Degree of sedation (mean score ±SD) (n = 30) determined before surgery, 60 min after oral
(Mid. + 60 min) and after i.v. (Mid. + 15 min) midazolam, and for up to 240 min after the administration
of RO or placebo (PL) i.v. *P < 0.05; ** P < 0.01 (Wilcoxon rank sum test).
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TABLB III. Number of patients whose scores of sedation were increased {Inc.) or decreased {Dec.) or whose
sedation scores remained unchanged {Same) after the administration of placebo {PL) or RO, up to 240 mn
(n = 30). **P < 0.01 Chi-square test
Score
Inc.
Same
Dec.
5 min
after
PL RO
1 0
9** 0
20** 30
15 min
after
PL RO
0 0
6 0
24 30
30 min
after
PL RO
1 0
4 0
25 30
60 min
after
PL RO
0 0
6 0
24 30
120 min
after
PL RO
0 0
2 1
28 29
240 min
after
PL RO
0 0
0 1
30 29
group, even though the degree of sedation after
placebo did decrease spontaneously. This differ-
ence remained significant for 30 min, after which
the degree of sedation was comparable in the two
groups (fig. 1). When the comparison was made
between the number of patients in whom sedation
increased or decreased after the injection of PL or
RO, the differences between the groups persisted
for less than 15 min (table III).
Data concerning the comprehension and collab-
oration using the simple tests already described
were difficult to interpret: there was only a
significant decrease in aptitude in both groups
after i.v. administration of midazolam. No differ-
ence was noted at any time when the two groups
were compared. When collaboration was tested
more objectively with the measures of vital
capacity (table IV), both groups decreased their
capacities after midazolam administered i.v. or by
mouth. When compared with placebo, RO im-
proved the performance significantly for less
than 15 min.
No difference in temporo-spatial orientation
could be noted at any time between the groups: a
similar degree of disorientation was observed after
oral and i.v. midazolam. After PL or RO injection,
equal number of patients in both groups were well
orientated.
The results concerning anterograde amnesia
are summarized in table V. Whereas no patient
had any impaired recall on the day before
operation, two-thirds of the patients, in both
groups, suffered from anterograde amnesia after
midazolam by mouth. After i.v. midazolam,
amnesia was present in 29 patients in group PL
and in 30 in group RO. RO reversed the amnesia
in all the patients for at least 15 min, while at that
time, in the PL group, 60% of the subjects still
had problems with recollection. Sixty minutes
after the injection of RO or PL, an increasing
TABLE IV.
PL
RO
Vital capacity {line im'n~l) {mean values ±SD).
Before
op.
2.7 ±0.8
2.7 ±0.8
60 min after
midazolam
by mouth
2.1 ±1
2.3±0.9
15 min
after i.v.
midazolam
1.2±1.2
1.1 ±1.2
PL =• placebo group; ,RO = 15-1788 group. *P < 0.05 unpaired t test
Time after PL or RO (min)
5 15
1.8±0.9 2.2±0.8
*
2.3 ±0.8 2.3 ±0.8
30 60
2.2 ±0.8 2.3 ±0.8
2.4±0.7 2.5±0.8
120
2.4 ±0.8
2.5 ±0.7
240
2.5±0.7
2.5 ±0.7
TABLE V.
PL
RO
Number of patients with anterograde amnesia (n = 30). PL =
***P < 0.001 {Chi-square test)
Before
op.
0
0
60 min after
midazolam
by mouth
20
21
15 min
after i.v.
midazolam
29
30
Time
5
18
***
0
placebo group ; RO » RO group.
after PL or RO (min)
15
17
***
2
60
22
***
7
120
00
 
00
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TABLE VI. Number of patients presenting side effects after
injection of placebo {PL) or RO 15-1788 {RO)
(n •= 30). ^Subjective side effects = anxiety, sensation of
impending death. *P = 0.052 (Chi-square)
Subjective
side
effectst Nausea
Brady-
cardia
Local
intol-
erance
PL
RO
number of patients suffered from amnesia again,
but significantly more after PL than after RO.
There was no difference between the two groups,
120 min after the administration of RO or PL.
The side effects are indicated in table VI: there
was no statistical difference between the two
groups, although 17% of patients described
feeling anxious after the injection of RO compared
with none after placebo (P = 0.052).
Two patients had to be excluded after the
administration of midazolam by mouth because
they became confused, disorientated and aggres-
sive; these reactions to BZD were completely
and quickly reversed by the injection of RO
O.lmgkg-1.
DISCUSSION
This study confirms the efficacy, usefulness and
safety of a BZD for pre- and peroperative sedation
under regional anaesthesia in elderly and fragile
patients, although an unexpected reaction occurred
in two out of the 62 patients (3.2%) studied.
It also corroborates the efficacy of RO 15-1788
as a specific BZD antagonist, since the amnesia
and sedation induced by midazolam were promptly
reversed by this drug. The absence of effect of RO
on temporo-spatial orientation and on the subjec-
tive evaluation of collaboration in both groups
reflects more the absence of accuracy of these two
tests than the inefficiency of the BZD antagonist
since, when collaboration was measured objectively
by asking patients to perform the vital capacity, it
improved significantly after the injection of RO.
Duration
The duration of action of RO varies according
to which variable is being considered—as described
previously (Lauven et al., 1985). In the present
study, the efficacy of RO lasted for less than
15 min when the incidence of improvement or
deterioration in collaboration and sedation were
considered; it lasted less than 60 min when the
effect on the incidence of amnesia and when scores
of sedation were taken into account. The duration
varied also according to the half-life of the BZD
administered and of the study design (O'Boyle et
al., 1983; Klotz et al., 1985). For example, when
midazolam is infused continuously after injection
of RO (Lauven et al., 1985), the duration of action
cannot be compared with our data.
As the half-life of midazolam is estimated to be
between 1.5 and 3.5 h (Dundee et al., 1984), the
drug was partially eliminated at the time of RO
injection; this explains why, 5 min after PL, 12 of
the 30 patients were no longer amnesic.
Safety and side effects
No major undesirable effect of RO was
observed: local tolerance was excellent. A light
burning sensation without any subsequent phleb-
itis at the site of injection occurred in 10% of
patients in each group, suggesting that this side
effect was attributable to the solvent (glycholic
acid, 40 % NaOH, lecithin, HC1, H,O) and not to
the active drug.
Although the incidence of anxiety and sensation
of impending death was not statistically significant
(P = 0.052), it occurred after the injection of RO
only. In spite of the fact that this kind of emotional
reaction was not described in most previous
investigations in man, it was observed in 100% of
the patients and considered as a severe complica-
tion by Louis and colleagues (1984). However, this
side effect occurred in less than 20% of our
patients and could be easily treated by reassurance
without the necessity to administer any sedative
drug. This state could be attributed to the specific
effect of the drug, influenced by the dose and rate
of administration or by the preoperative emotional
state which depends on environment, age and
severity of disease, or both. Since no anxiety was
observed when RO was administered alone
(Darragh et al., 1983) or to reverse previously
induced BZD sedation in many studies (Forster,
Rouiller et al. 1983), a specific effect of the drug
can be ruled out. The difference in incidence and
severity of anxiety where RO was administered
after the same dose of BDZ suggests that this
psychological side effect is most probably related
to the difference in emotional state between
patients (Editorial, 1975). Indeed, in the study by
Louis and colleagues, the subjects were stressed
because of a more severe disease (coronary
disease, undergoing aorto-coronary bypass sur-
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gery) and a more hostile environment (intensive
care unit) than our patients. The age of the
patients could also be an important factor, since it
is believed that elderly patients react differently to
stress.
The hypothesis which suggests that a stressful
situation enhances the production of endogenous
ligands (Lippa et al., 1978; Braestrup et al., 1983)
could explain the mechanism of the increased
incidence of anxiety after the administration of
RO in distressed patients. This theory is also
substantiated by the fact that RO can produce
a withdrawal syndrome (Lukas and Griffiths,
1982), which includes anxiety in patients chronic-
ally treated with BZD (Hallstrom and Lader,
1981).
Indications
The therapeutic value of this new compound
has yet to be determined. RO could be adminis-
tered to allow a differential diagnosis of a confused
state as, for example, during a transurethral
surgery, to differentiate water intoxication from
BZD-induced disorientation.
RO could be useful also when it is necessary to
awaken a patient in the peroperative period
(Harrington rodes, electrocoagulation of tri-
geminal nerve, etc.) or in intensive care unit to
allow neurological evaluation of sedated patients.
Although caution should be taken in its current
use, as mentioned by Ashton (1985), it has been
documented that RO could be useful in drug
intoxication in order either to treat a life-
threatening situation, or to prove or exclude
involvement of BZD (Scollo-Lavizzari, 1983;
Hofer and Scollo-Lavizzari, 1985). It has obviated
the need for mechanical ventilation in severe BZD
intoxication (Geller et al., 1984).
A paradoxical reaction is a serious side effect of
BZD, although it is rare and as yet not fully
understood (Greenblatt and Shader, 1974). The
subjects become confused and aggressive and can
harm themselves. In this study, two patients
presented such a reaction to midazolam; the
administration of RO was very effective in treating
and calming these patients, thus ensuring satisfac-
tory operating conditions.
When a short acting BZD is administered, RO
is probably unnecessary since, as shown in the
study, most of its clinical effectiveness was no
longer evident after 15 min. However, with
longer-acting BZD such as diazepam or flunitraz-
epam, RO could be more useful, but should be
administered under close supervision—as when
naloxone is administered after morphine (John-
stone et al., 1974), since its duration of action
is shorter than that of such BZD.
For this reason, the authors suggest that RO
should not be administered at the end of
outpatient anaesthesia, since it could provide a
transient improvement of alertness during which
the patients could be released from the hospital.
Since evidence of a withdrawal syndrome has
been reported in man as soon as after 6 weeks of
BZD treatment (Murphy, Owen and Tyrer, 1984),
RO should be administered with caution when
patients have received BZD for a long period.
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